Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simvastatin for Prevention of Anthracycline-Related Cardiac Toxicity
NCT02096588Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- May 2014
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of simvastatin in anthracycline-induced cardiotoxicity (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Change in Echocardiographic Global Longitudinal Strain at 15 weeks. Started May 2014; status: terminated.
02
Drugs
simvastatin
03
Conditions
anthracycline-induced cardiotoxicity
Beyond the preview
Go deeper on NCT02096588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02096588.